Cholinesterases, α-glycosidase, and carbonic anhydrase inhibition properties of 1H-pyrazolo[1,2-b]phthalazine-5,10-dione derivatives: Synthetic analogues for the treatment of Alzheimer's disease and diabetes mellitus

dc.contributor.authorTaslimi, Parham
dc.contributor.authorTurhan, Kadir
dc.contributor.authorTurkan, Fikret
dc.contributor.authorKaraman, Halide Sedef
dc.contributor.authorTurgut, Zuhal
dc.contributor.authorGülçin, İlhami
dc.contributor.authorTaslimi, Parham
dc.date.accessioned2025-10-18T10:11:00Z
dc.date.created2020
dc.date.issued2020
dc.departmentFakülteler, Fen Fakültesi, Biyoteknoloji Bölümü
dc.description.abstractIn this study, using the Cu(OTf)(2) catalyst, 1H-pyrazolo[1,2-b]phthalazine-5,10-dione derivative molecules were carried out in one step and with high yield (86-91%). The previously synthesized 1H-pyrazolo [1,2-b]phthalazine-5,10-dione derivatives, carbonic anhydrase I and II isozymes (hCA I and II), acetylcholinesterase (AChE), butyrylcholinesterase (BChE) and alpha-glycosidase (alpha-Gly) enzymes with K-i values in the range of 4.88-15.94 nM for hCA I, 7.04-20.83 nM for hCA II, 68.25-158.27 for AChE, 60.17-91.27 for BChE and 0.36-2.36 nM for alpha-Gly, respectively. In silico studies were performed on the molecules inhibiting hCA I, hCA II, AChE, BChE and alpha-Gly receptors. When we evaluated the data obtained in this work, we determined the inhibition type of the 1H-pyrazolo[1,2-b]phthalazine-5,10-dione derivatives at the receptors. Reference inhibitors were used for all enzymes.
dc.description.sponsorshipYildiz Technical University Research Fund [2012-01-02-GEP01]
dc.description.sponsorshipThe synthesis part of this study was supported by Yildiz Technical University Research Fund. Project Number: 2012-01-02-GEP01.
dc.identifier.doi10.1016/j.bioorg.2020.103647
dc.identifier.issn0045-2068
dc.identifier.issn1090-2120
dc.identifier.orcidGulcin, ilhami/0000-0001-5993-1668
dc.identifier.orcidTaslimi, Parham/0000-0002-3171-0633
dc.identifier.orcidKaraman, Halide Sedef/0000-0001-7925-7156;
dc.identifier.pmid32078939
dc.identifier.scopus2-s2.0-85079554683
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1016/j.bioorg.2020.103647
dc.identifier.urihttps://hdl.handle.net/11772/22160
dc.identifier.volume97
dc.identifier.wosWOS:000521282300011
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherAcademic Press Inc Elsevier Science
dc.relation.ispartofBioorganic Chemistry
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.relation.sdgGoal-03: Good Health and Well-Being
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzWoS_20251016
dc.subject1h-Pyrazolo[1, 2-B]Phthalazine-5
dc.subject10-Dione
dc.subjectCholinesterase
dc.subjectCarbonic Anhydrase
dc.subjectAlpha-Glycosidase
dc.subjectMolecular Docking
dc.titleCholinesterases, α-glycosidase, and carbonic anhydrase inhibition properties of 1H-pyrazolo[1,2-b]phthalazine-5,10-dione derivatives: Synthetic analogues for the treatment of Alzheimer's disease and diabetes mellitus
dc.typeArticle
dspace.entity.typePublication
relation.isAuthorOfPublicationdadfa319-65b8-4543-92b4-bea49e0139e9
relation.isAuthorOfPublication.latestForDiscoverydadfa319-65b8-4543-92b4-bea49e0139e9

Dosyalar